Weekly recap highlights ABEO royalty and milestone eligibility
The recap says Ultragenyx’s full FDA approval of FAYUVI could trigger potential royalties and a commercial milestone for Abeona Therapeutics. It also notes ZEVASKYN’s approval with University of Florida Health added as the eighth treatment center, plus a jump in retail sentiment and an indicated Roth Capital update.